News and insights

Groundbreaking Study on Fabry Disease and Severe Aortopathy Published in Circulation

Severe aortopathy and Fabry disease

Revolutionary Study on Severe aortopathy caused by Fabry disease.

 

We are thrilled to announce the publication in the prestigious scientific journal "Circulation", the fundamental study on the severe aortopathy caused by Fabry disease, conducted by a team of illustrious researchers from various prestigious institutions, including our own Aurora Polvani of Technoscience, Pontine Science and Technology Park, Latina, Italy. This study on severe aortopathy caused by Fabry disease was also published in the renowned scientific journal Circulation: Cardiovascular Imaging. In the paper, new cardiac complications associated with Fabry disease are evident and the critical need for timely diagnosis and intervention is underlined.

 

Understanding Fabry Disease

Fabry disease (FD) is a rare genetic disorder caused by mutations in the α-galactosidase A (AGA) gene, leading to a deficiency or absence of enzyme activity. This deficiency causes the accumulation of globotriaosylceramide (Gb3) in lysosomes, affecting various organs including the heart, kidneys and nervous system. Although Fabry disease is known to cause hypertrophic cardiomyopathy (HCM), this study is the first to document severe aortopathy and aneurysm formation in the aortic root, requiring surgery.

 

Visual for the study on Fabry disease and severe aortopathy published in Circulation
Severe aortopathy caused by Fabry disease

Case Study Highlights

The study described the case of a 62-year-old man with a history of Fabry disease, who developed severe hypertrophic cardiomyopathy and aortic root aneurysm. Despite enzyme replacement therapy (ERT), the patient's condition worsened over the course of 16 years, leading to significant complications including a 56 mm diameter aortic root aneurysm. Cardiovascular Magnetic Resonance (CMR) revealed thickening of the aortic wall and notable accumulation of glycosphingolipids.

Innovative Surgical Intervention

Severe aortopathy and Fabry disease
Severe aortopathy caused by Fabry disease

Due to the severity of the aortic aneurysm, the patient underwent a successful reimplantation procedure (David) using a Dacron Valsalva graft. This complex surgery was performed by the expert team from the Department of Cardiac Surgery at the European Hospital and Unicamillus University in Rome, Italy, involving the precise reimplantation of the aortic valve and restoration of the integrity of the aortic root.

Research Collaboration

The groundbreaking study on severe aortopathy caused by Fabry disease was made possible thanks to the collaboration of a team of first-rate researchers from multiple institutions:

  • Dr. Andrea Frustaci and Dr. Romina Verardo from IRCCS L. Spallanzani and IRCCS San Raffaele
  • Dr. Ruggero De Paulis from the European Hospital
  • Dr. Matteo Russo and Dr. Luigi Sansone from San Raffaele University, Rome
  • Dr. Manuel Belli from San Raffaele University of Rome
  • Dr. Nicola Galea from Sapienza University of Rome

Special recognition goes to Aurora Polvani of Technoscience for her significant contributions to the study.

Implications for Future Research and Treatment

The results of this study highlight the critical need for continued research and improved treatment strategies for Fabry disease. Early and accurate diagnosis, combined with effective therapeutic interventions, are essential to manage and mitigate the serious complications associated with this genetic disorder.

Technoscience is proud to be part of such a significant contribution to the medical field. We remain committed to advancing scientific research and fostering collaborations that lead to breakthrough discoveries. For detailed insights into this study, see the full publication in the journal Circulation https://www.ahajournals.org/journal/circ

 

How we turn ideas into projects

From initial assessment to validation: a collaborative method that turns knowledge, technologies and business needs into concrete initiatives.

01

Discovery and assessment

We start from the need, the scientific result or the available technology. We assess objectives, maturity, data, constraints and opportunities to define an initial realistic pathway.

02

Expertise and project design

We connect scientific and industrial partners and define activities, milestones, responsibilities and funding sources aligned with the expected outcome.

03

Validation and impact

We support experimentation, technology transfer and valorisation, measuring results and preparing the solution for its next step: adoption, partnership or market.

Related articles

Choose Technoscience!

To rapidly assess a project in biotech and translational medicine - from oncology and neuroscience to precision cardiology and telemedicine - we ask for: a clear clinical or industrial question, the available evidence (including negative findings), access to data and samples where applicable, a draft protocol (including ethical aspects), and hypotheses on biomarkers and endpoints. In return, we offer technical and scientific due diligence, the design of a credible TRL pathway and, where appropriate, support with regulatory strategy, validation and scalability.

Contatti biotech: professionisti pronti alla collaborazione e innovazione